Use of network pharmacology and molecular docking to explore the potential mechanism governing the efficacy of Jinhuaqinggan granules in the treatment of novel coronavirus-induced pneumonia
Journal Title: Precision Medicine Research - Year 2020, Vol 2, Issue 2
Abstract
Background: Now that the epidemic of new coronavirus pneumonia (corona virus disease 2019) is spreading all over the world, Jinhuaqinggan granules in the Chinese treatment plan has been proved to be an effective Chinese patent medicine for the treatment of corona virus disease 2019. Methods: This study aims to clarify the possible therapeutic mechanism governing the efficacy of Jinhuaqinggan granules in the treatment of corona virus disease 2019, through using network pharmacology and molecular docking. During the analysis, 227 active components were obtained and screened by using the ADME method. Furthermore, 282 Jinhuaqinggan granule targets and 56 common targets with corona virus disease 2019 were gathered from various databases. Then the protein-protein interaction network of Jinhuaqinggan granules and corona virus disease 2019 targets were constructed and 6 core targets were selected through network topology analysis. In addition, A total of 262 biological function annotation entries (P < 0.01) and 101 pathways (P < 0.01) were obtained by gene ontology functional enrichment analysis and Kyoto Encyclopedia of Genes and Genomes pathway analysis. Results: Molecular docking showed that quercetin, luteolin, kaempferol, wogonin and naringin had an affinity for SARS-CoV-2 3CL hydrolase and angiotensin-converting enzyme 2. Conclusion: corona virus disease 2019 can be prevented by the primary targets of Jinhuaqinggan granules. The most important bioactive components in Jinhuaqinggan granules—quercetin, naringenin, luteolin and wogonin—can play antiviral effect, anti-inflammatory storm, regulate immunity by regulating signal transducers and activators of transcription 1, interleukin 4, interferon-γ, heme oxygenase 1 and acting on the lipopolysaccharide response, toll-like receptor signaling pathway, mitogen-activated protein kinase signaling pathway, et al.
Authors and Affiliations
Heng Xu1 , Jin-Min Zhang1 , Yi-Zhuo Qiao1 , Wei Zhang1 , Zi-Tong Fu1 , Qing Zhao1*
Keywords
Related Articles
- EP ID EP685213
- DOI 10.12032/PMR201900030
- Views 158
- Downloads 0
Network pharmacological approach to explore the mechanisms of Lianhua Qingwen capsule in coronavirus disease 2019
Background: This study aimed to explore the molecular mechanisms of the active compounds of Lianhua Qingwen capsule in the treatment of coronavirus disease 2019 by using systemic pharmacology approach. Methods: In this...
Screening key target genes for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) based on bioinformatics and gene network
Background: To provide a reference for the clinical development of drugs to suppress severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Methods: Retrieving genes related to SARS-CoV-2 with Genecards database...
Use of network pharmacology and molecular docking to explore the potential mechanism governing the efficacy of Jinhuaqinggan granules in the treatment of novel coronavirus-induced pneumonia
Background: Now that the epidemic of new coronavirus pneumonia (corona virus disease 2019) is spreading all over the world, Jinhuaqinggan granules in the Chinese treatment plan has been proved to be an effective Chinese...
Screening key target genes for pulmonary arterial hypertension based on bioinformatics
Objective: Screening key target genes for pulmonary arterial hypertension (PAH) based on bioinformatics to provide a reference for the clinical development of drugs to cure PAH. Methods: The keyword “pulmonary arterial h...
A network pharmacology approach to investigate the mechanism of “Huangqi-Shanzhuyu” in the treatment of diabetic nephropathy
Background: To explore the action mechanism of Huangqi (Radix Astragali) and Shanzhuyu (Fructus Corni) in the treatment of diabetic nephropathy based on network pharmacology, aiming to provide a basis for clinical appli...